Jefferies Group LLC reaffirmed their buy rating on shares of MediWound Ltd. (NASDAQ:MDWD) in a report released on Thursday morning. The brokerage currently has a $10.00 target price on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on the stock. SunTrust Banks, Inc. restated a buy rating on shares of MediWound in a research report on Monday, June 26th. Oppenheimer Holdings, Inc. restated a buy rating and issued a $10.00 target price on shares of MediWound in a research report on Monday, September 18th. Zacks Investment Research upgraded shares of MediWound from a strong sell rating to a hold rating in a research report on Wednesday, August 2nd. Finally, ValuEngine lowered shares of MediWound from a sell rating to a strong sell rating in a research report on Friday, September 22nd. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $9.15.

MediWound (MDWD) traded up 7.00% on Thursday, reaching $5.35. The company’s stock had a trading volume of 94,486 shares. The firm’s market cap is $117.45 million. MediWound has a 12 month low of $4.25 and a 12 month high of $8.58. The firm’s 50 day moving average is $6.30 and its 200-day moving average is $6.53.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The business’s revenue was up 93.8% compared to the same quarter last year. During the same period last year, the business earned ($0.34) earnings per share. On average, equities research analysts anticipate that MediWound will post ($0.76) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/jefferies-group-llc-reaffirms-buy-rating-for-mediwound-ltd-mdwd/1601026.html.

Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN boosted its position in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares in the last quarter. Renaissance Technologies LLC boosted its position in MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its position in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after buying an additional 342,165 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares in the last quarter. Hedge funds and other institutional investors own 19.55% of the company’s stock.

About MediWound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Analyst Recommendations for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.